巣状分節性糸球体硬化症市場：上市済み薬剤およびパイプライン薬剤評価、臨床試験と競合情勢

当レポートでは、巣状分節性糸球体硬化症市場について調査し、疾患の疫学的概要とともに、上市済み薬剤およびパイプライン薬剤の評価、臨床試験動向、将来の発展動向などを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 疾患の情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬剤評価

• 主要な上市済み薬剤
• 作用機序別概要
• 投与経路別概要
• 分子タイプ別概要
• 薬剤プロファイルと売上予測

第5章 パイプライン薬剤評価

• 後期パイプライン薬
• 開発段階別概要
• 作用機序別概要
• 投与経路別概要
• 分子タイプ別概要
• 薬剤固有の相転移成功率（PTSR）および承認の可能性（LoA）
• 治療領域および適応症固有のPTSRおよびLoA

第6章 臨床試験の評価

• 歴史的概要
• 相別の概要
• ステータス別の概要
• 進行中および計画中の試験の相別概要
• 仮想コンポーネント別の臨床試験
• 地理的概要
• 地域別の単一国および多国籍試験
• 相別内訳のスポンサー主要20社
• ステータス別内訳付きスポンサー主要20社
• エンドポイントステータス別の概要
• 人種と民族別概要
• 登録データ
• 臨床試験サイトの上位20か国
• 世界の主要20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第7章 取引情勢

• 合併、買収、戦略的提携、地域別
• 最近の合併、買収、および戦略的提携

第8章 商業的評価

• 主要な市場参入企業

第9章 将来の市場促進要因

第10章 付録

• 調査手法
• 調査手法-PTSRおよびLoA分析
• 著者について
• お問合せ
• 免責事項

This reports provides a data-driven overview of the current and future competitive landscape in Focal Segmental Glomerulosclerosis therapeutics.

Key Highlights

• In 2022, there will be more than 169,000 diagnosed prevalent cases of FSGS across 16 pharmaceutical markets.
• There are several marketed genericized drugs for the treatment of FSGS, which are mostly immune-suppressing in nature.
• A total of three pipeline drugs for FSGS are in Phase III globally.
• Commercial sponsors dominate clinical trial development in FSGS, with China emerging as the key countries for conducting trials in FSGS.
• Deals involving companies with FSGS assets were very scarce, with only one completed strategic alliance.
• Regulatory approval in the US for Travere Therapeutic's sparsentan for FSGS is expected in June 2023.

Scope

GlobalData's Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Focal Segmental Glomerulosclerosis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Overview by Molecule Type
• 4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

• 5.1 Late-stage Pipeline Drugs
• 5.2 Overview by Development Stage
• 5.3 Overview by Mechanism of Action
• 5.4 Overview by Route of Administration
• 5.5 Overview by Molecule Type
• 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

• 6.1 Historical Overview
• 6.2 Overview by Phase
• 6.3 Overview by Status
• 6.4 Overview by Phase for Ongoing and Planned Trials
• 6.5 Trials with Virtual Components
• 6.6 Geographic Overview
• 6.7 Single-Country and Multinational Trials by Region
• 6.8 Top 20 Sponsors with Breakdown by Phase
• 6.9 Top 20 Sponsors with Breakdown by Status
• 6.10 Overview by Endpoint Status
• 6.11 Overview by Race and Ethnicity
• 6.12 Enrollment Data
• 6.13 Top 20 countries for Trial Sites
• 6.14 Top 20 Sites Globally
• 6.15 Feasibility Analysis - Geographic Overview
• 6.16 Feasibility Analysis - Benchmark Models

7 Deals Landscape

• 7.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

• 8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

• 10.1 Methodology
• 10.2 Methodology - PTSR and LoA Analysis
• 10.3 About the Authors
• 10.4 Contact Us
• 10.5 Disclaimer